A big welcome to John Bonasera, who has just joined our team focused on organizational strategy & effectiveness! Read our press release to learn more about John and his background... https://lnkd.in/g9kdGNSP #biotech #pharmaceuticals #organizationalexcellence #organizationalstrategy
Blue Matter
Unternehmensberatung
South San Francisco, California 25.846 Follower:innen
New Ideas. Better Results.
Info
Our Work Blue Matter is a specialized management consulting firm, founded in San Francisco with offices in the US and Europe. We work with life sciences clients to address business issues across the company and product value chain. Our collaborations with bio-pharmaceutical industry leaders focus on providing the strategic insights necessary to create and achieve their visions. Our Story Blue Matter was born out of a vision to bring together a group of people that are passionate about applying consulting skills to help shape great ideas, products, and companies. Blue Matter is founded on the principle of placing the client business issue at the center of every engagement, developing a customized approach, and staffing the engagement appropriately to ensure that we achieve the desired results. Our Team Our team includes experienced strategy consultants with significant professional and educational experience relevant to the life science industry. We work collaboratively to solve the problems of senior leaders of life science companies, and deliver value through providing innovative and actionable solutions. We value personal and professional growth, and emphasize our employees’ development as a key success metric for the company. We are actively looking for qualified new team members. For more information, contact [email protected] for US-based opportunities and [email protected] for Europe-based opportunities.
- Website
-
http://www.bluematterconsulting.com
Externer Link zu Blue Matter
- Branche
- Unternehmensberatung
- Größe
- 201–500 Beschäftigte
- Hauptsitz
- South San Francisco, California
- Art
- Privatunternehmen
- Gegründet
- 2012
Orte
Beschäftigte von Blue Matter
Updates
-
For an emerging #biotech company seeking a deal or partnership, it's critical to develop a robust commercial proposition that communicates value to potential investors in a compelling, evidence-based manner. This paper describes how to do that effectively >> https://bit.ly/4dLEJDL Authors: Vinay Torani, Pankaj Oza, Sam Calderwood, & Tahel Noy #pharmaceuticals #biopharma #emergingbiopharma
Communicating the Value of Biopharma Assets to Potential Investors - Blue Matter Consulting
https://bluematterconsulting.com
-
New Article >> Overview of the #schizophrenia treatment landscape, the advent of muscarinic therapies, & a look at how #biopharma companies can succeed in the space. Authors Jack Bower & Julia Margulis provide a detailed look... >> https://lnkd.in/eNBgbAcQ #CNStherapies #mentalhealth #biotech #pharmaceuticals #CNS
Exploring Muscarinic Agonists in Schizophrenia - Blue Matter Consulting
https://bluematterconsulting.com
-
A big welcome to our newest intern in London: Peter Nix! Peter will be working with us for the next 5 weeks. He’ll be supporting a product positioning project using secondary research to help inform product differentiation across scientific, clinical, and commercial criteria. Peter is attending the University of Cambridge, studying biochemistry, and he’s heading into the 4th year of his Master’s program. He’s also an avid rower and often gets up at 5:30 am to go rowing before class. Welcome, Peter! #Consulting #ConsultingCareers #BestTeamEver #Biotech #Pharmaceuticals
-
As deal-making activity continues to heat up in #biopharma, companies on either side of a transaction need a systematic approach for determining the value of a therapeutic asset. In this article, we outline such an approach: https://lnkd.in/eR6F4tuV Authors: Vinay Torani, Tahel Noy, Shalin Shah, Prateek Patel #biotech #pharmaceutical #businessdevelopment #licensing
Adopting a Holistic Approach to Pharma/Biotech Asset Evaluation - Blue Matter Consulting
https://bluematterconsulting.com
-
An emerging #biopharma company seeking to maximize the value of its pipeline asset(s) must communicate that value to potential investors in a compelling & credible manner. In this article, we describe 6 key success factors for communicating value to investors. >> https://lnkd.in/eDwCCXcC Authors: Vinay Torani, Pankaj Oza, Tahel Noy, & Sam Calderwood #biopharma #biotech #pharmaceuticals
Communicating Value to Investors (pt. 2) - Blue Matter Consulting
https://bluematterconsulting.com
-
What are the top 5 key success factors for commercialization orgs within midsize & large biopharma companies? Howard Brock provides the list, based on conversations with 14 commercial leaders in midsize/large companies. >> https://lnkd.in/efyeSD_G #biotech #pharmaceuticals #biopharma #organizationalstrategy
5 Success Factors for Commercial Orgs in Midsize / Large Pharma
https://bluematterconsulting.com
-
Our summer off-site meetings are very important for all our teams. The NY team recently held their off-site at Scribner’s Lodge in the Catskill Mountains of NY. There was a team training event, as well as lots of fun activities, including hatchet throwing, yoga, candle-making, tie-dyeing, & time to relax with colleagues. #TeamBuilding #BestTeamEver #Consulting #ConsultingCareers
-
+4
-
What are the top 5 key success factors for commercialization orgs within emerging biopharma companies? Howard Brock provides the list, based on conversations with 10 commercial leaders in emerging companies. >> https://lnkd.in/eJeNc3NB #biotech #pharmaceuticals #biopharma
5 Success Factors for Commercial Orgs in Emerging Biopharma
https://bluematterconsulting.com
-
#CNS is a complex therapeutic space. In this article, Julia Margulis explores a key challenge for those developing therapies in CNS (part 1 of a new series) >> https://lnkd.in/e_JDWxPF #biotech #pharmaceuticals #centralnervoussystem
Challenges in CNS Development & Commercialization #1: Heterogeneity of CNS as a Disease Category - Blue Matter Consulting
https://bluematterconsulting.com